Codebreaker Tx has filed a notice of an exempt offering of securities to raise $7,399,611.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Codebreaker Tx is raising up to $7,399,611.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Codebreaker Tx
Codebreaker Labs is a deep-tech company with a platform that generates causal genomics data at scale showing how variants, pathways, and targets drive health and disease. This creates a new category of data for training genomics AI, enabling teams to move beyond noisy signals to clear evidence: Association whispers, Causation speaks. Our data moat grows and compounds with real-world use, enabling faster decisions and better outcomes while boosting research velocity. Our first application is a genomics AI software co-developed with leading childrens hospitals to speed diagnosis and guide next steps in care. From this foundation, our roadmap extends into biopharma and translational research powering target discovery, indication selection, and development decisions with high-resolution causal evidence. Codebreaker Labs. Programming biology to transform genomic medicine.

To learn more, visit https://codebreakerlabs.io/
LinkedIn: https://www.linkedin.com/company/codebreaker-labs/

Contact:
Ryan Gill, Chief Executive Officer
https://www.linkedin.com/in/ryan-t-gill-9388238/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.